ARTICLE | Clinical News
VB 1953: Ph I started
November 2, 2016 11:09 PM UTC
Vyome began an open-label, U.S. Phase I trial to evaluate topical VB 1953 applied twice daily for 14 days in about 14 patients....
BCIQ Company Profiles
Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
Vyome began an open-label, U.S. Phase I trial to evaluate topical VB 1953 applied twice daily for 14 days in about 14 patients....
BCIQ Company Profiles